Advertisement

Topics

Neumentum Company Profile

11:29 EDT 18th June 2018 | BioPortfolio

Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute postoperative pain that requires analgesia at the opioid level, and to reduce the need for opioids in clinical settings.


News Articles [1 Associated News Articles listed on BioPortfolio]

Neumentum Confirms Type B Meeting with FDA and Announces New Chief Medical and Scientific Officers

-- May 8 Type B meeting confirmed to discuss the clinical development program for lead product candidate NTM-001, which has potential to treat moderately severe acute postoperativ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Neumentum

Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid an...

More Information about "Neumentum" on BioPortfolio

We have published hundreds of Neumentum news stories on BioPortfolio along with dozens of Neumentum Clinical Trials and PubMed Articles about Neumentum for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neumentum Companies in our database. You can also find out about relevant Neumentum Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record